How effective is CAR T cell therapy?

CAR T cell therapy has shown promising results in clinical trials, with high response rates and durable remissions observed in some patients. However, the therapy does not work for everyone, and further research is needed to improve its efficacy and address issues such as resistance and relapse.

How much does CAR T cell therapy cost?

CAR T cell therapy is a costly treatment, with current prices ranging from $373,000 to $475,000 per patient. However, some insurance companies and government programs may cover the cost of the therapy for eligible patients.

How is CAR T cell therapy administered?

CAR T cell therapy is administered intravenously, usually as a one-time infusion.

CAR T-Cell Therapies Market Size

Content

Executive Summary Introduction Market Dynamics Market Analysis Segments Analysis Cross-Segments Analysis Competitive Landscape Regulatory Landscape Market Trends and Insights Investment Analysis Future Outlook Appendix

Executive Summary

Market Overview
Key Findings
Market Trends
Strategic Recommendations

Introduction

Definition of CAR T-Cell Therapy
Scope of the Report
Research Methodology
Market Segmentation

Market Dynamics

Drivers
- Increasing Cancer Incidence
- Technological Advancements
- Growing Investment in Research and Development
Restraints
- High Treatment Costs
- Complex Manufacturing Processes
Opportunities
- Expanding Applications
- Emerging Markets
Challenges
- Regulatory Hurdles
- Side Effects and Safety Concerns

Market Analysis

Historical Market Size and Growth
Market Forecast
Market Share Analysis
Pricing Analysis

Segments Analysis

By Drug Type

Axicabtagene Ciloleucel
Tisagenlecleucel
Brexucabtagene Autoleucel
Others

By Indication

Lymphoma
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma (MM)
Others

By End User

Hospitals
Cancer Treatment Centers

By Geography

North America
Europe
Asia-Pacific
Latin America
The Middle East and Africa

Cross-Segments Analysis

By Drug Type

Axicabtagene Ciloleucel
- By Indication
  - Lymphoma: High revenue and volume due to FDA approvals and clinical efficacy.
  - Acute Lymphocytic Leukemia (ALL): Moderate revenue and volume, significant market in the U.S. and Europe.
  - Chronic Lymphocytic Leukemia (CLL): Lower revenue, less prevalent indication.
  - Multiple Myeloma (MM): Emerging market with increasing volume and value as approvals expand.
  - Others: Includes niche indications with smaller market share.
- By End User
  - Hospitals: Significant revenue due to high costs of therapy and large patient base.
  - Cancer Treatment Centers: Growing volume as specialized centers adopt this therapy.
- By Geography
  - North America: Dominates market value and volume due to extensive clinical use and high adoption.
  - Europe: Growing market, with Germany and the UK leading in adoption.
  - Asia-Pacific: Emerging market with increasing adoption in China and Japan.
  - Latin America: Smaller market with growth potential.
  - The Middle East and Africa: Niche market with expanding opportunities.
Tisagenlecleucel
- By Indication
  - Lymphoma: High market value and volume; well-established in various regions.
  - Acute Lymphocytic Leukemia (ALL): Strong presence in North America and Europe.
  - Chronic Lymphocytic Leukemia (CLL): Moderate market share; emerging in new regions.
  - Multiple Myeloma (MM): Increasing market with growing clinical evidence.
  - Others: Niche applications with developing market presence.
- By End User
  - Hospitals: High revenue due to comprehensive therapy administration.
  - Cancer Treatment Centers: Increasing volume with specialized treatment settings.
- By Geography
  - North America: Leading market with high adoption rates and significant revenue.
  - Europe: Growing market with strong performance in major countries.
  - Asia-Pacific: Emerging market with rising adoption, especially in China and Japan.
  - Latin America: Developing market with gradual growth.
  - The Middle East and Africa: Limited but growing presence.
Brexucabtagene Autoleucel
- By Indication
  - Lymphoma: Moderate market value and volume; expanding indications.
  - Acute Lymphocytic Leukemia (ALL): Emerging presence, with growing market potential.
  - Chronic Lymphocytic Leukemia (CLL): Developing market; limited by clinical use.
  - Multiple Myeloma (MM): Growing indication with increasing market share.
  - Others: Niche indications with smaller market impact.
- By End User
  - Hospitals: Significant revenue from high-cost therapies.
  - Cancer Treatment Centers: Growing volume due to specialized treatment focus.
- By Geography
  - North America: Leading market with high adoption and revenue.
  - Europe: Growing market with expanding usage.
  - Asia-Pacific: Emerging market with increasing adoption.
  - Latin America: Developing market with gradual growth.
  - The Middle East and Africa: Limited market presence but potential for expansion.
Others
- By Indication
  - Lymphoma: Smaller revenue and volume compared to leading drugs, but growing.
  - Acute Lymphocytic Leukemia (ALL): Niche applications with developing market share.
  - Chronic Lymphocytic Leukemia (CLL): Limited market presence.
  - Multiple Myeloma (MM): Emerging with potential for increased market share.
  - Others: Various indications with small but growing market segments.
- By End User
  - Hospitals: Revenue generation from high-cost therapies.
  - Cancer Treatment Centers: Increasing volume with specialized treatment offerings.
- By Geography
  - North America: Developing market with high adoption rates.
  - Europe: Emerging market with growing revenue.
  - Asia-Pacific: Increasing market share with rising adoption.
  - Latin America: Small but expanding market.
  - The Middle East and Africa: Limited presence with potential for future growth.

By Indication

Lymphoma
- By Drug Type
  - Axicabtagene Ciloleucel: High market value and volume.
  - Tisagenlecleucel: Significant market share with high adoption.
  - Brexucabtagene Autoleucel: Moderate market presence; expanding.
  - Others: Growing market for emerging therapies.
- By End User
  - Hospitals: Major revenue due to extensive treatment.
  - Cancer Treatment Centers: Increasing volume as specialty centers adopt therapy.
- By Geography
  - North America: Dominates in market value and volume.
  - Europe: Significant market presence, especially in Germany and the UK.
  - Asia-Pacific: Emerging market with growing adoption.
  - Latin America: Developing market with potential growth.
  - The Middle East and Africa: Niche market with expanding opportunities.
Acute Lymphocytic Leukemia (ALL)
- By Drug Type
  - Axicabtagene Ciloleucel: Strong market presence with growing adoption.
  - Tisagenlecleucel: High market value and volume.
  - Brexucabtagene Autoleucel: Emerging market presence.
  - Others: Developing market for niche therapies.
- By End User
  - Hospitals: High revenue from extensive therapy use.
  - Cancer Treatment Centers: Increasing volume as centers specialize in ALL.
- By Geography
  - North America: Leading market with significant adoption.
  - Europe: Growing market with strong performance.
  - Asia-Pacific: Increasing market share with rising adoption.
  - Latin America: Developing market with gradual growth.
  - The Middle East and Africa: Limited market presence with potential for expansion.
Chronic Lymphocytic Leukemia (CLL)
- By Drug Type
  - Axicabtagene Ciloleucel: Limited market share; developing applications.
  - Tisagenlecleucel: Moderate market presence.
  - Brexucabtagene Autoleucel: Developing presence.
  - Others: Niche market with growing potential.
- By End User
  - Hospitals: Revenue generation from specialized treatments.
  - Cancer Treatment Centers: Increasing volume due to specialized focus.
- By Geography
  - North America: Emerging market with growing adoption.
  - Europe: Developing market with expanding usage.
  - Asia-Pacific: Increasing market presence.
  - Latin America: Small market with potential growth.
  - The Middle East and Africa: Limited but growing market.
Multiple Myeloma (MM)
- By Drug Type
  - Axicabtagene Ciloleucel: Emerging market with growing revenue.
  - Tisagenlecleucel: Increasing market presence.
  - Brexucabtagene Autoleucel: Developing market.
  - Others: Growing market with emerging therapies.
- By End User
  - Hospitals: Significant revenue from therapy administration.
  - Cancer Treatment Centers: Growing volume as specialized centers adopt therapy.
- By Geography
  - North America: Leading market with high adoption.
  - Europe: Growing market with increasing adoption.
  - Asia-Pacific: Emerging market with rising potential.
  - Latin America: Developing market with gradual growth.
  - The Middle East and Africa: Limited market presence with potential for expansion.
Others
- By Drug Type
  - Axicabtagene Ciloleucel: Niche market presence for other indications.
  - Tisagenlecleucel: Developing presence in less common indications.
  - Brexucabtagene Autoleucel: Emerging market for niche applications.
  - Others: Various therapies with growing market segments.
- By End User
  - Hospitals: Revenue generation from various therapies.
  - Cancer Treatment Centers: Increasing volume as specialized therapies become available.
- By Geography
  - North America: Developing market with high adoption rates.
  - Europe: Growing market with emerging indications.
  - Asia-Pacific: Rising market presence with increasing adoption.
  - Latin America: Small but expanding market.
  - The Middle East and Africa: Limited market presence with potential growth.

By End User

Hospitals
- By Drug Type
  - Axicabtagene Ciloleucel: High revenue due to high-cost therapy administration.
  - Tisagenlecleucel: Significant volume and revenue.
  - Brexucabtagene Autoleucel: Growing revenue as adoption increases.
  - Others: Smaller but developing revenue streams.
- By Indication
  - Lymphoma: High market value and volume.
  - Acute Lymphocytic Leukemia (ALL): Significant therapy use.
  - Chronic Lymphocytic Leukemia (CLL): Moderate market presence.
  - Multiple Myeloma (MM): Growing market value.
  - Others: Niche indications with developing market.
- By Geography
  - North America: Leading market with high adoption and revenue.
  - Europe: Growing market with significant revenue.
  - Asia-Pacific: Increasing market presence with rising adoption.
  - Latin America: Developing market with potential growth.
  - The Middle East and Africa: Limited presence but expanding opportunities.
Cancer Treatment Centers
- By Drug Type
  - Axicabtagene Ciloleucel: Growing volume and revenue.
  - Tisagenlecleucel: Significant market presence.
  - Brexucabtagene Autoleucel: Emerging market with increasing adoption.
  - Others: Developing presence for niche therapies.
- By Indication
  - Lymphoma: High volume and revenue.
  - Acute Lymphocytic Leukemia (ALL): Increasing adoption and volume.
  - Chronic Lymphocytic Leukemia (CLL): Developing market presence.
  - Multiple Myeloma (MM): Growing indication with increasing volume.
  - Others: Niche applications with expanding market.
- By Geography
  - North America: Leading market with high adoption and revenue.
  - Europe: Growing presence with increasing volume.
  - Asia-Pacific: Emerging market with rising adoption.
  - Latin America: Developing market with gradual growth.
  - The Middle East and Africa: Limited presence with potential for expansion.

By Geography

North America
- By Drug Type
  - Axicabtagene Ciloleucel: Dominant market with high revenue and volume.
  - Tisagenlecleucel: Significant market share.
  - Brexucabtagene Autoleucel: Emerging market presence.
  - Others: Developing market for niche therapies.
- By Indication
  - Lymphoma: Highest market value and volume.
  - Acute Lymphocytic Leukemia (ALL): Significant adoption.
  - Chronic Lymphocytic Leukemia (CLL): Growing market.
  - Multiple Myeloma (MM): Increasing presence.
  - Others: Various indications with emerging market potential.
- By End User
  - Hospitals: Major revenue and volume.
  - Cancer Treatment Centers: Growing market presence.
Europe
- By Drug Type
  - Axicabtagene Ciloleucel: Significant market presence with growing adoption.
  - Tisagenlecleucel: Increasing market value and volume.
  - Brexucabtagene Autoleucel: Developing presence.
  - Others: Smaller market for niche therapies.
- By Indication
  - Lymphoma: High market presence.
  - Acute Lymphocytic Leukemia (ALL): Growing market.
  - Chronic Lymphocytic Leukemia (CLL): Emerging market.
  - Multiple Myeloma (MM): Increasing market value.
  - Others: Various indications with developing presence.
- By End User
  - Hospitals: Significant market presence.
  - Cancer Treatment Centers: Growing volume and revenue.
Asia-Pacific
- By Drug Type
  - Axicabtagene Ciloleucel: Emerging market with increasing adoption.
  - Tisagenlecleucel: Growing market presence.
  - Brexucabtagene Autoleucel: Developing presence.
  - Others: Niche therapies with growing market.
- By Indication
  - Lymphoma: Increasing market share.
  - Acute Lymphocytic Leukemia (ALL): Emerging presence.
  - Chronic Lymphocytic Leukemia (CLL): Growing market value.
  - Multiple Myeloma (MM): Developing market.
  - Others: Various indications with emerging presence.
- By End User
  - Hospitals: Growing revenue and volume.
  - Cancer Treatment Centers: Increasing adoption.
Latin America
- By Drug Type
  - Axicabtagene Ciloleucel: Developing market presence.
  - Tisagenlecleucel: Growing adoption.
  - Brexucabtagene Autoleucel: Emerging market.
  - Others: Niche therapies with gradual growth.
- By Indication
  - Lymphoma: Increasing market presence.
  - Acute Lymphocytic Leukemia (ALL): Growing market value.
  - Chronic Lymphocytic Leukemia (CLL): Developing presence.
  - Multiple Myeloma (MM): Emerging market.
  - Others: Various indications with potential growth.
- By End User
  - Hospitals: Developing market with growing adoption.
  - Cancer Treatment Centers: Increasing volume and revenue.
The Middle East and Africa
- By Drug Type
  - Axicabtagene Ciloleucel: Limited presence with potential for growth.
  - Tisagenlecleucel: Growing market.
  - Brexucabtagene Autoleucel: Emerging presence.
  - Others: Developing niche therapies.
- By Indication
  - Lymphoma: Expanding market presence.
  - Acute Lymphocytic Leukemia (ALL): Increasing adoption.
  - Chronic Lymphocytic Leukemia (CLL): Developing market.
  - Multiple Myeloma (MM): Growing presence.
  - Others: Niche indications with expanding market.
- By End User
  - Hospitals: Limited presence with potential growth.
  - Cancer Treatment Centers: Emerging market with growing volume.

Competitive Landscape

Market Share Analysis
Company Profiles
Key Players
- Johnson & Johnson Services, Inc.
- ALLOGENE THERAPEUTICS
- Lonza
- Aurora Biopharma
- Cartesian Therapeutics, Inc.
- Novartis
- Bristol-Myers Squibb company
- Gilead Sciences
- Curocell Inc
- JW Therapeutics
- Other Key Players
Competitive Strategies
- Product Launches
- Mergers and Acquisitions
- Partnerships and Collaborations
Recent Developments

Regulatory Landscape

Regulatory Approvals
Market Authorization Processes
Current Guidelines and Standards

Market Trends and Insights

Technological Advancements
Innovations in Therapy Development
Patient and Physician Perspectives

Investment Analysis

Funding and Investments
Venture Capital and Private Equity
Market Entry Strategies

Future Outlook

Market Opportunities
Emerging Trends
Forecast and Predictions

Appendix

Data Sources
Glossary of Terms
List of Abbreviations
Contact Information

Insight Code: 5028
No. of Pages: 150
Format: PDF/PPT/Excel
Published: May 2024
Report Covered: [Revenue + Volume]
Historical Year: 2021-2022
Base Year: 2023
Estimated Years: 2024-2033

Proceed To Buy

Global Deep Dive Analysis

USD 3800

Single Region (NA,EU,APAC,LA,MEA)

USD 2900

Databook

USD 1900

Cross-Sectional Analysis

USD 5500

We use cookies to improve your experience

CAR T-Cell Therapies Market Size | 29.8% - CAGR

CAR T-Cell Therapies Market Size (USD 88.52 Bn) by 2032